Trade Panbela Therapeutics, Inc. - PBLA CFD

Panbela Therapeutics, Inc. Company profile

About Panbela Therapeutics Inc

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing disruptive therapeutics for the treatment of patients with cancer. The Company is engaged in the commercial development of a polyamine analogue for pancreatic cancer. Its product candidate includes SBP-101, which is a proprietary polyamine analogue that accumulates in the exocrine pancreas acinar cells due to its chemical structure. The Company is conducting Phase I a/I b study of the safety, efficacy and pharmacokinetics of SBP-101 administered in combination with two standard-of-care chemotherapy agents, gemcitabine and nab-paclitaxel.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Panbela Therapeutics Inc revenues was not reported. Net loss increased 70% to $6.6M. Higher net loss reflects Research and Development - Balancing increase of 90% to $3.2M (expense), General and administrative -Bal increase of 69% to $2.5M (expense), Other income decrease from $55K (income) to $611K (expense).